COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a trailblazer in digital health that is revolutionizing chronic condition management to help transform lives, today announced that the company’s 20th U.S. patent was granted by the U.S. Patent and Trademark Office on April 13, 2021.
“Welldoc’s twentieth patent awarded marks a milestone in the company’s history of developing pioneering platform solutions that enable better chronic condition management,” said Kevin McRaith, President and CEO of Welldoc. “Our ever-growing IP portfolio allows us to enhance our integrated platform solutions and continually adapt our AI engine to provide the best feedback and data visualizations. Through clinical trials, FDA clearances and our robust patent portfolio, we are applying the same level of rigor and scrutiny to our digital health offerings, as other facets of the healthcare industry apply to their products. Welldoc’s approach is backed by eight 510(k)s and more than 55 peer-reviewed clinical posters and publications.”
The company’s offerings include the award-winning BlueStar® diabetes management solution, which uses digital health to provide a comprehensive platform with education, real-time feedback and an Insulin Adjustment Program. BlueStar is cleared by the U.S. Food and Drug Administration (FDA) for adults with type 1 or type 2 diabetes. The platform is device-agnostic, allowing for seamless integration with a patient’s existing blood glucose meters, pharmacies, labs, and activity and fitness trackers.
Welldoc® is revolutionizing chronic condition management to help transform lives. BlueStar®, an FDA-cleared digital health solution, guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their conditions and enhancing connections to their healthcare team. Welldoc streamlines the relationships between payers, employers and healthcare systems resources, with the goal of improving population health and reducing costs of chronic care. For more information, visit www.welldoc.com.